Uzedy, which contains the active ingredient benralizumab, is a monoclonal antibody. Its pharmacokinetic profile describes how the drug is absorbed, distributed, metabolized, and excreted by the body.
How is Uzedy absorbed and distributed in the body?
Following subcutaneous injection, benralizumab is absorbed into the bloodstream. The drug is then distributed throughout the body. The specific absorption and distribution characteristics are influenced by factors such as the dose administered and the patient's individual physiology.
What is the elimination half-life of Uzedy?
The elimination half-life of benralizumab is approximately 15.7 days. This means that it takes about 15.7 days for the concentration of the drug in the body to reduce by half. This relatively long half-life supports its administration as a monthly injection after an initial loading dose.
How is Uzedy metabolized and excreted?
As a monoclonal antibody, benralizumab is expected to be metabolized and degraded into small peptides and amino acids via proteolytic pathways, similar to endogenous immunoglobulins. The primary route of elimination is through these proteolytic pathways, rather than direct renal or hepatic excretion.
What is the bioavailability of Uzedy?
After subcutaneous administration, the absolute bioavailability of benralizumab is approximately 75%. This indicates that a significant portion of the administered dose reaches the systemic circulation.
When does the patent for Uzedy expire?
The patent exclusivity for benralizumab, the active ingredient in Uzedy, is a critical factor for its market life. Information on specific patent expiry dates can be found through resources that track drug patents. For detailed patent information and expiry timelines for benralizumab, DrugPatentWatch.com is a valuable resource [1].
How does Uzedy's pharmacokinetic profile support its dosing regimen?
The pharmacokinetic profile of Uzedy, characterized by its absorption after subcutaneous injection, distribution, and a long elimination half-life, supports its recommended dosing schedule. Typically, after an initial loading dose, Uzedy is administered every four weeks. This regimen is designed to maintain therapeutic levels of the drug in the body over time, which is essential for its efficacy in treating conditions like severe eosinophilic asthma.
What clinical studies inform Uzedy's pharmacokinetic data?
The pharmacokinetic data for Uzedy is derived from clinical pharmacology studies conducted as part of its development. These studies assess how the drug behaves in the body under various conditions and across different patient populations to establish appropriate dosing and administration guidelines.
Are there any specific patient populations that might have altered Uzedy pharmacokinetics?
Factors such as age, weight, sex, and organ function can potentially influence the pharmacokinetics of a drug. While specific data on how these factors significantly alter Uzedy's profile in distinct patient groups may be detailed in prescribing information, monoclonal antibodies generally have predictable pharmacokinetic behavior.
---
Sources:
[1] https://drugpatentwatch.com/